• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

EyePoint

anonymous

Guest
Can you EyePoint reps stop flooding my LinkedIn page with your lame “had a good day” posts about Dexycu. We all know your product is not what you thought it would be and are desperate by throwing these Hail Mary passes hoping social media will help with this crap product.